Liposome News and Research

Latest Liposome News and Research

YM BioSciences receives approval to expand enrolment in Phase I/II clinical trial of CYT387

YM BioSciences receives approval to expand enrolment in Phase I/II clinical trial of CYT387

Erbitux can now be used in Japan as 1st-line treatment for mCRC: Merck Serono

Erbitux can now be used in Japan as 1st-line treatment for mCRC: Merck Serono

Merck Serono, EMD Serono suspend global clinical development program for Stimuvax temporarily

Merck Serono, EMD Serono suspend global clinical development program for Stimuvax temporarily

Abstract about Phase I/II trial of ThermoDox in RCW accepted for presentation at ASCO 2010

Abstract about Phase I/II trial of ThermoDox in RCW accepted for presentation at ASCO 2010

YM BioSciences: Two posters on nimotuzumab accepted for presentation at AACR

YM BioSciences: Two posters on nimotuzumab accepted for presentation at AACR

Bio-Path Holdings' liposomal Grb-2 IND receives FDA clearance to proceed into clinical trials

Bio-Path Holdings' liposomal Grb-2 IND receives FDA clearance to proceed into clinical trials

YM Biosciences announces increase of registered direct offering to $17.5M

YM Biosciences announces increase of registered direct offering to $17.5M

YM Biosciences to raise $15M in registered direct offering of common stock

YM Biosciences to raise $15M in registered direct offering of common stock

YM BioSciences files Form 6K regarding certain nimotuzumab US patents

YM BioSciences files Form 6K regarding certain nimotuzumab US patents

Celsion to commence Phase II Study of ThermoDox and RFA for CRLM

Celsion to commence Phase II Study of ThermoDox and RFA for CRLM

Fourth-quarter and full-year 2009 results announced by Celsion

Fourth-quarter and full-year 2009 results announced by Celsion

YM Biosciences to present JAK1/2 inhibiting small molecule and vascular disrupting agent data at Cancer Conference

YM Biosciences to present JAK1/2 inhibiting small molecule and vascular disrupting agent data at Cancer Conference

DMC recommends Celsion to continue its Phase III ThermoDox clinical trial for primary liver cancer

DMC recommends Celsion to continue its Phase III ThermoDox clinical trial for primary liver cancer

YM BioSciences receives additional AeroLEF patents in U.S.

YM BioSciences receives additional AeroLEF patents in U.S.

YM BioSciences-Cytopia merger complete

YM BioSciences-Cytopia merger complete

YM BioSciences' nimotuzumab Phase II trials: FDA advises patient enrollment

YM BioSciences' nimotuzumab Phase II trials: FDA advises patient enrollment

Erbitux improves survival of mCRC patients with KRAS wild-type tumors

Erbitux improves survival of mCRC patients with KRAS wild-type tumors

YM BioSciences announces results of cancer antibody-radionuclide conjugate development collaboration

YM BioSciences announces results of cancer antibody-radionuclide conjugate development collaboration

FDA issues Fast Track Designation to Sopherion Therapeutics' Myocet

FDA issues Fast Track Designation to Sopherion Therapeutics' Myocet

Phase II clinical trial results of Liposome-Entrapped Paclitaxel announced

Phase II clinical trial results of Liposome-Entrapped Paclitaxel announced